64 results about "Remyelination" patented technology

Method for reversing demyelination in a patient having a demyelinating disorder may include detecting one or more biomarkers for demyelination from the patient, receiving, in an implanted vagus nerve stimulator, a command to apply a remyelinating stimulation to the patient based on a level of the detected one or more biomarkers for demyelination; and applying electrical stimulation to the patient's vagus nerve from the implanted vagus nerve stimulator to reverse demyelination and increase remyelination of the patient's nerves. The electrical stimulation may be adjusted based on the level of the detected one or more biomarkers.

The present disclosure provides, in one aspect, compounds, compositions, and methods for reducing and / or inhibiting the activity of p38gamma. In certain embodiments, the compounds, compositions, and methods of the disclosure are useful for promoting remyelination. In certain embodiments, the compounds, compositions, and methods of the disclosure are useful for treating, preventing, and / or ameliorating one or more diseases or disorders in a subject, including but not limited to multiple sclerosis (MS), inflammatory disease, and cancer.

The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

Disclosed herein are methods and compositions for treating a demyelinating disease, such as multiple sclerosis, by administering to a subject suffering from the disease at least one Retinoid X receptor gamma (RXRy) agonist and at least one member selected from a Liver X Receptor (LXR) antagonist, CYP51 inhibitor, TM7SF2 inhibitor, EBP inhibitor, and combinations thereof.

The invention relates to application of GMFB in preparation of a medicine for treating traumatic optic neuropathy. Research finds that on the third day of a rat ONC model, compared with normal control, GMFB expression is remarkably up-regulated; cholera toxin B subunit (Cholera Toxin Subunit B, CTB) tracing shows that the axons of a rat ONC model with the GMFB knocked out are remarkably lengthened (compared with those of a wild rat ONC model), and LFB (luxoLuxol Fast Blue) myelination staining shows that remyelination of the denatured axons can be effectively improved, axon regeneration is promoted, and the visual function is improved by knockout of the GMFB.

The subject matter described herein relates to compounds of Formula A and pharmaceutically acceptable salts thereof that promote myelination, methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds to treat conditions, such as myelination-related conditions.

The present application relates to a kind of myelin repair auxiliary method based on neural signal modeling.The method obtains the multi-modal neural signal data such as electroencephalogram signal of individual to be rehabilitated and is preprocessed, forms preprocessed data set;Subsequently, individualized time series modeling process is executed, and the time series characteristic representation including nerve conduction velocity recovery rate, phase consistency and neural pathway integrity is generated, and individualized calibration is carried out by dynamic baseline updating mechanism.The calibrated feature representation is input to the pre-trained deep learning inference engine.The inference engine outputs myelin repair index and imbalance risk score, which is used to represent the degree of repair and predict future abnormal risk.Based on the above index, a set of intervention parameters is generated, including electrical stimulation intervention parameters, virtual rehabilitation training task difficulty and rehabilitation training rhythm, and further forming control instructions to configure virtual rehabilitation training environment and electrical stimulation execution interface, so as to realize the individualized assistance and dynamic optimization of myelin regeneration repair.

Provided is a medicine for promoting induction of differentiation of oligodendrocyte progenitor cells into oligodendrocytes, and a medicine for promoting remyelination. The medicine contains a vitamin D derivative represented by formula (1) or a pharmaceutically acceptable salt or solvate thereof and used in combination with an immunosuppressant.

The disclosure provides methods for (i) treating multiple sclerosis in patient, (ii) treating a patient having symptoms of multiple sclerosis, (iii) preventing the onset of multiple sclerosis symptoms in patient having multiple sclerosis or predisposed to multiple sclerosis; (iv) promoting or enhancing immunomodulation and remyelination and / or myelin repair in a subject in need thereof; (v) a neuroinflammatory disorder; (vi) Amyotrophic Lateral Sclerosis; or (vii) a demyelinating disease or disorder or a hypomyelinating condition, each method comprising administering a therapeutically effective amount of a bryostatin compound to the patient.

The invention relates to the technical field of new application of medicines, in particular to application of G15 to treatment of white matter injury based on promotion of cerebrovascular generation, and finds that the G15 has the effect of promoting cerebrovascular generation, can promote myelination insufficiency caused by hypoxia in the early development stage and can improve neurological dysfunction caused by hypoxia, and the G15 has the effect of promoting cerebrovascular generation. Moreover, myelin sheath regeneration of a local demyelination area after the adult can be promoted, so that the effect of directly treating the white matter injury from the pathological aspect is achieved. The invention provides a new application of G15 in treating white matter injury and long-term neurological dysfunction by promoting cerebrovascular generation.

The invention relates to the field of biological medicine, in particular to application of a reagent for up-regulating PEX5 expression level or improving PEX5 protein activity in preparation of a medicine for treating demyelination diseases. A lentivirus infection experiment and lysolecithin are utilized to induce a mouse demyelination model, it is found that PEX5 can promote differentiation and maturation of oligodendroglia cells and remyelination and repair of demyelination mice, and ganciclovir can promote differentiation of the oligodendroglia cells and effectively relieve demyelination diseases by promoting expression of PEX5. PEX5 can be used as a drug intervention target, and a drug for promoting expression or function of PEX5 can be used as a potential therapeutic drug for demyelination diseases.

The present application provides O-GlcNAc glycosidase (O-GlcNAcase, OGA) inhibitors and their applications for promoting remyelination. Specifically, by comparing the promoting effects of different types of OGA inhibitors on OPC differentiation and remyelination in the models of OPC differentiation and remyelination, the OGA inhibitors with drugability of the present application are obtained. The OGA inhibitors of the present application have wide application value in preventing and / or treating demyelination and its related diseases.

The invention provides an animal body electrode myelination electric control system and method, and the system comprises an electrode mechanism which comprises an electrode substrate, and a first electrode, a second electrode, a third electrode, a fourth electrode, a fifth electrode and a sixth electrode which are disposed on the electrode substrate. The electrode mechanism, the resistor and the waveform function generator are sequentially connected in series to form an electric control system. When the electrode mechanism is used, the electrode mechanism is implanted into a to-be-operated object and then fixed on soft tissue of an injured area through an absorbable suture, and the two ends of a series electric control circuit are connected with an external power supply to form an electric control system. The first electrode, the second electrode, the third electrode, the fourth electrode, the fifth electrode and the sixth electrode are externally connected with copper wires for electrode stimulation selection, multi-path and multi-direction electrical stimulation scheme adjustment is achieved, growth of nerve axons can be promoted, remyelination of the axons can be promoted, recovery of nerve functions is accelerated, and popularization and application are facilitated.

4-Hydroxyphenyl-2H-indazol-5-ol compounds are estrogen receptor beta ligands that have immunomodulatory properties and increase oligodendrocyte survival, differentiation, and remyelination. The compounds, compositions, and kits are useful in the treatment of multiple sclerosis and endometriosis.

The present invention relates to nutritional compositions and infant formulas for promoting myelination of the brain. More specifically, the present invention relates to compositions for promoting, supporting or optimizing a subject's re-myelination, and / or brain structure, and / or brain connectivity, and / or one or more of cognitive potential, learning potential, and intellectual potential, and / or cognitive function.

The present invention relates to combination therapies targeting inhibitors of O-GlcNAc glycoside hydrolases and antibodies. Specifically, the invention provides application of a preparation combination of an OGA inhibitor and an antibody, and the preparation combination is used for combined treatment of demyelination and related diseases. The OGA inhibitor and the antibody are jointly applied to individuals suffering from myelin sheath injury or aplastic disorder, the promoting effect on myelin sheath regeneration and the regulating effect on immune cells can be achieved, the OGA inhibitor and the antibody have a synergistic effect, myelin sheath regeneration can be more remarkably promoted, and the OGA inhibitor and the antibody have wide application prospects in prevention and / or treatment of demyelination and related diseases.

To provide a pharmaceutical composition for treating nervous system disorders by inducing remyelination, neuroprotection, and immunomodulation.SOLUTION: A pharmaceutical composition comprising a therapeutically effective amount of a RXR agonist for use in combination with a thyroid hormone in the treatment of demyelination or neuroinflammation associated with a central nervous system disorder, the RXR agonist is 3, 7-dimethyl-6 (S), 7 (S) - methano, 7 - [1,1,4,4 - tetramethyl - 1,2,3,4 - tetrahydronaphth-7-yl] 2 (E), 4 (E) heptadienoic acid, and the RXR agonist is used in combination with a thyroid hormone to provide greater improvement in a central nervous system disorder than either the RXR agonist or the thyroid hormone alone.SELECTED DRAWING: Figure 1

The invention discloses application of steroid saponin of trillium tschonoskii maxim to preparation of a medicine for treating vascular dementia, and relates to the technical field of medicines. Animal experiments prove that the berberis apiacea steroid saponin can improve the spatial reference learning function of cerebral ischemia rats, improve the spatial reference memory function of the cerebral ischemia rats and enhance the long-term memory function of the cerebral ischemia rats. In addition, brain tissue damage and white matter structure damage of rats suffering from cerebral ischemia can be relieved, axonal myelin sheath microstructure reconstruction and white matter fiber reconstruction of the rats suffering from cerebral ischemia are promoted, and myelin sheath regeneration of rats suffering from vascular dementia is promoted. Network pharmacological analysis finds that the age grass total steroid saponin has a wide regulation effect on OPCs and OLs cell components and molecular functions, and further, OPCs differentiation myelin sheath inhibition related factors are regulated and controlled, and white matter myelin sheath regeneration is promoted.

The application belongs to the technical field of biological drugs, and particularly relates to a preparation method of genetically modified human bone marrow mesenchymal stem cells and application thereof in treating nervous system diseases, in particular, multiple sclerosis. The human bone marrow mesenchymal stem cells are double-modified by brain-derived neurotrophic factor (BDNF) and anti-S1PR5 nanobody, so that the activity of the human bone marrow mesenchymal stem cells is improved, the survival of neurons or oligodendrocytes is promoted, cell apoptosis is inhibited, and myelin regeneration is promoted, and the human bone marrow mesenchymal stem cells can be applied to nervous system diseases, in particular, multiple sclerosis.

The invention provides a composite active dressing for neural restoration and a preparation method and application thereof, and relates to the technical field of medical materials. The composite active dressing comprises a transdermal inner layer and a small extracellular vesicle slow-release outer layer, the transdermal inner layer is of a membrane-shaped structure and comprises a composite active component and a hydrogel matrix material, and the composite active component is selected from one or more of an anti-inflammatory component, a microcirculation improving component, an antioxidant component and a neurotrophic component; the small extracellular vesicle sustained-release outer layer is of a three-dimensional network structure and comprises small extracellular vesicles and a hydrogel matrix material. According to the invention, stable loading and layered deep delivery and release of the small extracellular vesicles are realized, the inflammatory response and microcirculation state of an injured part are improved, proliferation migration and remyelination of Schwann cells can be promoted, and axon regeneration and effective repair of nerve injury can also be promoted.

The subject matter described herein relates to compounds of formula (I) and pharmaceutically acceptable salts thereof that promote myelin, methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds to treat conditions, such as myelin-related conditions. # imgabs0 #

The present invention provides an NSDP1 micropeptide and its application in repairing demyelinating damage, belonging to the field of biomedicine technology. The NSDP1 polypeptide of the present invention can significantly promote the remyelination of axonal demyelinating damage, providing a new idea and method for repairing nerve demyelinating damage.

The invention provides hydrogel for repairing peripheral nerve injury as well as a preparation method and application of the hydrogel, and belongs to the field of biomedical engineering materials. The hydrogel disclosed by the invention is good in biocompatibility, has degradability, contains a double-layer cross-linked network structure, has the wetting characteristic of common hydrogel, and also has the advantages of collagen antigenicity, biodegradability, high biocompatibility, cell adaptability, tissue regeneration promotion and the like. The hydrogel can effectively promote regeneration and remyelination of nerve fibers, can promote gastrocnemius muscle recovery and promote motor function recovery, and has a good application prospect.

The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

The invention discloses a substance for targeted inhibition of IRF1 gene expression and application thereof. The substance comprises nucleic acid for specifically silencing the IRF1 gene. The nucleic acid is siRNA (small interfering Ribonucleic Acid) containing the following sequence or a cloning vector for transcriptional coding of the following sequence: 5 '-TCACCAAGAACCAGGAA-3'. The siRNA is applied to preparation of drugs for regulating differentiation and apoptosis of oligodendrocyte precursor cells and drugs for promoting remyelination and repairing spinal cord injury. According to the invention, IRF1 is taken as a molecular intervention target, and IRF1 expression is reduced or inhibited, so that apoptosis of oligodendrocyte precursor cells is significantly inhibited, differentiation and maturation of the oligodendrocyte precursor cells are promoted, and the purpose of promoting myelin sheath recovery of spinal cord injury is achieved.

The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.

The invention relates to a myelin sheath repair auxiliary method based on neural signal modeling. According to the method, multi-modal neural signal data such as electroencephalogram signals of a to-be-recovered individual are obtained and preprocessed, and a preprocessed data set is formed; then, an individualized time sequence modeling process is executed, time sequence feature representation containing indexes such as the nerve conduction speed recovery rate, the phase consistency and the neural pathway integrity is generated, and individualized calibration is carried out through a dynamic baseline updating mechanism. The calibrated feature representation is input to a pre-trained deep learning inference engine. The inference engine outputs a myelin sheath repair index and an imbalance risk score for representing a repair degree and predicting a future abnormal risk. An intervention parameter set is generated based on the indexes, the intervention parameter set comprises electrical stimulation intervention parameters, virtual rehabilitation training task difficulty and rehabilitation training rhythms, and a control instruction is further formed to configure a virtual rehabilitation training environment and an electrical stimulation execution interface, so that personalized assistance and dynamic optimization of myelin sheath regeneration and repair are realized.

The subject matter described herein relates to compounds of formula (I) and pharmaceutically acceptable salts thereof that promote myelin, methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds to treat conditions, such as myelin-related conditions. # imgabs0 #

The multi-electrode cell myelination electric control system comprises a multi-electrode plate, a resistor and a waveform function generator, the multi-electrode plate, the resistor and the waveform function generator are sequentially connected in series to form a series electric control circuit, and the two ends of the series electric control circuit are connected with an external power source to form the electric control system. The multi-electrode plate comprises a flexible substrate and electrodes, a first electrode area and a second electrode area are arranged on the flexible substrate, and six electrodes are arranged in each of the first electrode area and the second electrode area. The multi-electrode plate, the resistor and the waveform function generator are sequentially connected in series to form a series electric control circuit, the two ends of the series electric control circuit are connected with an external power supply to form an electric control system, multi-path and multi-direction electric stimulation scheme adjustment is achieved by controlling the electrodes on the two sides to discharge, growth of nerve axons can be promoted, and the nerve stimulation effect is improved. And remyelination of axons can be promoted, so that recovery of neurological functions is accelerated, and popularization and application are facilitated.

An O-GlcNAcase (OGA) inhibitor for promoting remyelination and use thereof. Specifically, the OGA inhibitor with druggability is obtained by comparing the promoting effects of different types of OGA inhibitors on oligodendrocyte precursor / progenitor cell differentiation and remyelination in an OPC differentiation model and a remyelination model. The OGA inhibitor has wide application value in preventing and / or treating demyelination and related diseases thereof.